Design of biological equivalence programs for therapeutic biotechnology products in clinical development: a perspective.
The determination of biological equivalence requires that studies are conducted to establish that two molecules, two formulations, of two dosing regimens, for example, are indistinguishable with respect to safety and efficacy profiles that have been previously established. The criteria that are used to establish biological equivalence will depend on the nature of the change (e.g., molecular, process, formulation), the stage of the development program, the duration of treatment, and the intended clinical indications. Key components of an equivalence program include chemical characterization, in vitro and in vivo bioactivity against reference material, pharmacokinetics, and safety. Special considerations for patient populations, endogenous concentrations, environmental factors, immunogenicity, assay methodology, biochemical identity, pharmacodynamic equivalence, and statistical methodology are discussed. In addition, the role of preclinical in vivo assessments is addressed. Specific case studies provide insight into the varied nature of approaches that are currently employed.
Genentech, Incorporated, South San Francisco, California, USA.
J
J
Mordenti
J A
JA
Cavagnaro
J D
JD
Green
D001709:Biotechnology / Q000379:methods; D002986:Clinical Trials as Topic / Q000379:methods*; D015195:Drug Design; D006801:Humans; D011994:Recombinant Proteins / Q000493:pharmacokinetics*; D013810:Therapeutic Equivalency
D011994:Recombinant Proteins